On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results